Credit Capital Investments’s Charles River Laboratories CRL Stock Holding History

Credit Capital Investments’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,323	Closed	-$260K	–	63
2022 Q3	$260K	Buy	+1,323	New	+$286K	0.35%	49
2022 Q2	–	Sell	-1,050	Closed	-$298K	–	61
2022 Q1	$298K	Buy	+1,050	New	+$324K	0.28%	51

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Credit Capital Investments's CRL Position: Q4 2022 in Review

Credit Capital Investments sold out of Charles River Laboratories (CRL) in Q4 2022, closing a stake of 1,323 shares — an estimated $260K sold.

Credit Capital Investments first reported a position in CRL in Q1 2022 and held it in 2 quarters. The position peaked at $298K in Q1 2022. 627 funds tracked by Wall St. Rank hold CRL as of Q4 2022.

Credit Capital Investments reported no remaining Charles River Laboratories position as of Q4 2022 after selling out during the quarter.
Credit Capital Investments sold 1,323 Charles River Laboratories shares in Q4 2022, an estimated $260K.
Credit Capital Investments first reported a position in Charles River Laboratories in Q1 2022 and held it in 2 quarters.
Credit Capital Investments's Charles River Laboratories position peaked at $298K in Q1 2022.
627 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2022.

Based on Credit Capital Investments's 13F filing for Q4 2022, filed 14 Feb 2023.